Clarity Pharmaceuticals (ASX:CU6) Up 0.66% — Should This Nuclear Medicine Biotech Be on Your Watchlist?

• R&D expenditure increased A$24.2 million to A$91.1 million in FY2026

Sonal Goyal | 04 September 2026

CSL Ltd (ASX:CSL) Edges Lower — Should You Keep It on Your Radar?

• CSL applied to ASX forQuotationof an additional 834,408 ordinary shares in September

Sonal Goyal | 04 September 2026

• Underlying net profit declined 9% to A$194.8 million in HY26

Sonal Goyal | 04 September 2026

• Company provides cognitive-testing services for pharmaceutical and clinical research customers

Sonal Goyal | 04 September 2026

• Net loss after tax increased to A$25.183 million from A$16.406 million in FY25

Sonal Goyal | 04 September 2026

• Erik Van den Enden appointed as Chief Financial Officer in September 2026

Sonal Goyal | 04 September 2026

• H1 EBITDA of A$907 million, up 10%

Sonal Goyal | 04 September 2026

• Company listed on the ASX in October 2025 following a refreshed strategy

Sonal Goyal | 04 September 2026

•GAAPgrossMarginincreased 170 basis points to 61.1%

Sonal Goyal | 04 September 2026

• EBITDA increased 4.2% to A$1.069 billion and EBIT rose 2.9% to A$298.6 million

Sonal Goyal | 04 September 2026